These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 20383867

  • 1. A quality of life comparison in cyclosporine- and tacrolimus-treated renal transplant recipients across Canada.
    Prasad GV, Nash MM, Keough-Ryan T, Shapiro RJ.
    J Nephrol; 2010; 23(3):274-81. PubMed ID: 20383867
    [Abstract] [Full Text] [Related]

  • 2. A numerical scale comparison of renal transplant recipient experience with and opinions about calcineurin inhibitors.
    Prasad GV, Nash MM, McFarlane PA, Zaltzman JS.
    Nephron Clin Pract; 2004; 97(2):c35-40. PubMed ID: 15218328
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK, Montagnino G, Del Castillo D, Margreiter R, Sperschneider H, Olbricht CJ, Krüger B, Ortuño J, Köhler H, Kunzendorf U, Stummvoll HK, Tabernero JM, Mühlbacher F, Rivero M, Arias M, European Tacrolimus vs Cyclosporin Microemulsion Renal Transplantation Study Group.
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [Abstract] [Full Text] [Related]

  • 4. Conversion from cyclosporine microemulsion to tacrolimus-based immunoprophylaxis improves cholesterol profile in heart transplant recipients with treated but persistent dyslipidemia: the Canadian multicentre randomized trial of tacrolimus vs cyclosporine microemulsion.
    White M, Haddad H, Leblanc MH, Giannetti N, Pflugfelder P, Davies R, Isaac D, Burton J, Chan M, Azevedo E, Howlett J, Ignaszewski A, Busque S, Cantarovich M, Ferguson R, Genest J, Ross H.
    J Heart Lung Transplant; 2005 Jul; 24(7):798-809. PubMed ID: 15982605
    [Abstract] [Full Text] [Related]

  • 5. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 6. The effects of HLA mismatching and immunosuppressive therapy on early rejection outcome in pediatric heart transplant recipients.
    Herzberg GZ, Rossi AF, Courtney M, Gelb BD.
    J Heart Lung Transplant; 1998 Dec 15; 17(12):1195-200. PubMed ID: 9883760
    [Abstract] [Full Text] [Related]

  • 7. Tacrolimus and quality of life after kidney transplantation--a multicenter study.
    Bohlke M, Rocha M, Gomes RH, Marini SS, Terhorst L, Barcellos FC, Hallal PC, Casarini D, Irigoyen MC.
    Clin Transplant; 2006 Dec 15; 20(4):504-8. PubMed ID: 16842529
    [Abstract] [Full Text] [Related]

  • 8. Renal function in patients with cadaveric kidney transplants treated with tacrolimus or cyclosporine.
    Gonzalez Molina M, Morales JM, Marcen R, Campistol JM, Oppenheimer F, Serón D, Gil-Vernet S, Capdevila L, Andrés A, Lampreave I, Del Castillo D, Cabello M, Burgos D, Valdés F, Anaya F, Escuín F, Arias M, Pallardó L, Bustamante J.
    Transplant Proc; 2007 Sep 15; 39(7):2167-9. PubMed ID: 17889126
    [Abstract] [Full Text] [Related]

  • 9. Three-year posttransplant graft survival in renal-transplant patients with graft function at 6 months receiving tacrolimus or cyclosporine microemulsion within a triple-drug regimen.
    Irish W, Sherrill B, Brennan DC, Lowell J, Schnitzler M.
    Transplantation; 2003 Dec 27; 76(12):1686-90. PubMed ID: 14688516
    [Abstract] [Full Text] [Related]

  • 10. Long-term graft function with tacrolimus and cyclosporine in renal transplantation: paired kidney analysis.
    Cheung CY, Chan HW, Liu YL, Chau KF, Li CS.
    Nephrology (Carlton); 2009 Dec 27; 14(8):758-63. PubMed ID: 20025685
    [Abstract] [Full Text] [Related]

  • 11. Single-center experience with tacrolimus versus cyclosporine-Neoral in renal transplant recipients.
    Boots JM, van Duijnhoven EM, Christiaans MH, Nieman FH, van Suylen RJ, van Hooff JP.
    Transpl Int; 2001 Dec 27; 14(6):370-83. PubMed ID: 11793034
    [Abstract] [Full Text] [Related]

  • 12. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
    Bumbea V, Kamar N, Ribes D, Esposito L, Modesto A, Guitard J, Nasou G, Durand D, Rostaing L.
    Nephrol Dial Transplant; 2005 Nov 27; 20(11):2517-23. PubMed ID: 15985508
    [Abstract] [Full Text] [Related]

  • 13. Subclinical inflammation in renal transplant recipients: impact of cyclosporine microemulsion versus tacrolimus.
    Lauzurica R, Pastor MC, Bayes B, Malumbres S, Homs M, Llopis MA, Bonet J, Romero R.
    Transplant Proc; 2007 Sep 27; 39(7):2170-2. PubMed ID: 17889127
    [Abstract] [Full Text] [Related]

  • 14. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
    Hasenbein W, Albani J, Englert C, Spehr A, Grabhorn E, Kemper MJ, Burdelski M, Ganschow R.
    Pediatr Transplant; 2006 Dec 27; 10(8):938-42. PubMed ID: 17096762
    [Abstract] [Full Text] [Related]

  • 15. Impaired erythropoietin production in liver transplant recipients: the role of calcineurin inhibitors.
    Bardet V, Junior AP, Coste J, Lecoq-Lafon C, Chouzenoux S, Bernard D, Soubrane O, Lacombe C, Calmus Y, Conti F.
    Liver Transpl; 2006 Nov 27; 12(11):1649-54. PubMed ID: 17058250
    [Abstract] [Full Text] [Related]

  • 16. Improvement of quality of life in tacrolimus-based pediatric renal transplant recipients and their caregivers, including donors.
    Hasegawa A, Oshima S, Takahashi K, Uchida K, Ito K, Sonoda T.
    Transplant Proc; 2005 May 27; 37(4):1771-3. PubMed ID: 15919461
    [Abstract] [Full Text] [Related]

  • 17. Five-year study of tacrolimus as secondary intervention versus continuation of cyclosporine in renal transplant patients at risk for chronic renal allograft failure.
    Jevnikar A, Arlen D, Barrett B, Boucher A, Cardella C, Cockfield SM, Rush D, Paraskevas S, Shapiro J, Shoker A, Yilmaz S, Zaltzman JS, Kiberd B.
    Transplantation; 2008 Oct 15; 86(7):953-60. PubMed ID: 18852662
    [Abstract] [Full Text] [Related]

  • 18. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun 15; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 19. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.
    Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, Campistol JM, Racusen L, Polinsky MS, Goldberg-Alberts R, Li H, Scarola J, Neylan JF, Sirolimus CONVERT Trial Study Group.
    Transplantation; 2009 Jan 27; 87(2):233-42. PubMed ID: 19155978
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.